Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial

Concurrent chemoradiotherapy (CRT) with blockade of the PD-1 pathway may enhance immune-mediated tumor control through increased phagocytosis, cell death, and antigen presentation. The NiCOL phase 1 trial (NCT03298893) is designed to determine the safety/tolerance profile and the recommended phase-I...

Full description

Saved in:
Bibliographic Details
Published inNature communications Vol. 14; no. 1; pp. 3698 - 15
Main Authors Rodrigues, Manuel, Vanoni, Giulia, Loap, Pierre, Dubot, Coraline, Timperi, Eleonora, Minsat, Mathieu, Bazire, Louis, Durdux, Catherine, Fourchotte, Virginie, Laas, Enora, Pouget, Nicolas, Castel-Ajgal, Zahra, Marret, Gregoire, Lesage, Laetitia, Meseure, Didier, Vincent-Salomon, Anne, Lecompte, Lolita, Servant, Nicolas, Vacher, Sophie, Bieche, Ivan, Malhaire, Caroline, Huchet, Virginie, Champion, Laurence, Kamal, Maud, Amigorena, Sebastian, Lantz, Olivier, Chevrier, Marion, Romano, Emanuela
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 22.06.2023
Nature Publishing Group
Nature Portfolio
Subjects
13/31
13/51
38
45
45/23
631/67/580
692/4028/67/1517/1371
692/53/2423
Antigen presentation
Antigens
B7-H1 Antigen
Brachytherapy
Cancer
CD11c antigen
CD3 antigen
CD4 antigen
CD8 antigen
Cell death
Cervical cancer
Chemoradiotherapy
Chemotherapy
Female
Foxp3 protein
Health risks
Humanities and Social Sciences
Humans
Immunological tolerance
Immunotherapy
Lung Neoplasms - drug therapy
Lymphocytes
Lymphocytes T
Macrophages
Monoclonal antibodies
multidisciplinary
Myeloid cells
Nivolumab - therapeutic use
Patients
PD-1 protein
PD-L1 protein
Phagocytosis
Programmed Cell Death 1 Receptor
Radiation therapy
Response rates
Risk assessment
Science
Science (multidisciplinary)
Survival
Targeted cancer therapy
Tumor cells
Tumors
Uterine Cervical Neoplasms - drug therapy
Online AccessGet full text

Cover

Abstract Concurrent chemoradiotherapy (CRT) with blockade of the PD-1 pathway may enhance immune-mediated tumor control through increased phagocytosis, cell death, and antigen presentation. The NiCOL phase 1 trial (NCT03298893) is designed to determine the safety/tolerance profile and the recommended phase-II dose of nivolumab with and following concurrent CRT in 16 women with locally advanced cervical cancer. Secondary endpoints include objective response rate (ORR), progression free survival (PFS), disease free survival, and immune correlates of response. Three patients experience grade 3 dose-limiting toxicities. The pre-specified endpoints are met, and overall response rate is 93.8% [95%CI: 69.8–99.8%] with a 2-year PFS of 75% [95% CI: 56.5–99.5%]. Compared to patients with progressive disease (PD), progression-free (PF) subjects show a brisker stromal immune infiltrate, higher proximity of tumor-infiltrating CD3 + T cells to PD-L1 + tumor cells and of FOXP3 + T cells to proliferating CD11c + myeloid cells. PF show higher baseline levels of PD-1 and ICOS-L on tumor-infiltrating EMRA CD4 + T cells and tumor-associated macrophages, respectively; PD instead, display enhanced PD-L1 expression on TAMs, higher peripheral frequencies of proliferating Tregs at baseline and higher PD-1 levels at week 6 post-treatment initiation on CD4 and CD8 T cell subsets. Concomitant nivolumab plus definitive CRT is safe and associated with encouraging PFS rates. Further validation in the subset of locally advanced cervical cancer displaying pre-existing, adaptive immune activation is warranted. A combination of chemoradiotherapy followed by brachytherapy is recommended for patients with locally-advanced cervical cancer (LACC), however there is still a high risk of disease recurrence. Here the authors report clinical outcomes and immunologic correlates of a clinical trial of the PD-1 inhibitor nivolumab in combination with chemoradiotherapy in LACC patients.
AbstractList Concurrent chemoradiotherapy (CRT) with blockade of the PD-1 pathway may enhance immune-mediated tumor control through increased phagocytosis, cell death, and antigen presentation. The NiCOL phase 1 trial (NCT03298893) is designed to determine the safety/tolerance profile and the recommended phase-II dose of nivolumab with and following concurrent CRT in 16 women with locally advanced cervical cancer. Secondary endpoints include objective response rate (ORR), progression free survival (PFS), disease free survival, and immune correlates of response. Three patients experience grade 3 dose-limiting toxicities. The pre-specified endpoints are met, and overall response rate is 93.8% [95%CI: 69.8–99.8%] with a 2-year PFS of 75% [95% CI: 56.5–99.5%]. Compared to patients with progressive disease (PD), progression-free (PF) subjects show a brisker stromal immune infiltrate, higher proximity of tumor-infiltrating CD3 + T cells to PD-L1 + tumor cells and of FOXP3 + T cells to proliferating CD11c + myeloid cells. PF show higher baseline levels of PD-1 and ICOS-L on tumor-infiltrating EMRA CD4 + T cells and tumor-associated macrophages, respectively; PD instead, display enhanced PD-L1 expression on TAMs, higher peripheral frequencies of proliferating Tregs at baseline and higher PD-1 levels at week 6 post-treatment initiation on CD4 and CD8 T cell subsets. Concomitant nivolumab plus definitive CRT is safe and associated with encouraging PFS rates. Further validation in the subset of locally advanced cervical cancer displaying pre-existing, adaptive immune activation is warranted. A combination of chemoradiotherapy followed by brachytherapy is recommended for patients with locally-advanced cervical cancer (LACC), however there is still a high risk of disease recurrence. Here the authors report clinical outcomes and immunologic correlates of a clinical trial of the PD-1 inhibitor nivolumab in combination with chemoradiotherapy in LACC patients.
Concurrent chemoradiotherapy (CRT) with blockade of the PD-1 pathway may enhance immune-mediated tumor control through increased phagocytosis, cell death, and antigen presentation. The NiCOL phase 1 trial (NCT03298893) is designed to determine the safety/tolerance profile and the recommended phase-II dose of nivolumab with and following concurrent CRT in 16 women with locally advanced cervical cancer. Secondary endpoints include objective response rate (ORR), progression free survival (PFS), disease free survival, and immune correlates of response. Three patients experience grade 3 dose-limiting toxicities. The pre-specified endpoints are met, and overall response rate is 93.8% [95%CI: 69.8-99.8%] with a 2-year PFS of 75% [95% CI: 56.5-99.5%]. Compared to patients with progressive disease (PD), progression-free (PF) subjects show a brisker stromal immune infiltrate, higher proximity of tumor-infiltrating CD3+ T cells to PD-L1+ tumor cells and of FOXP3+ T cells to proliferating CD11c+ myeloid cells. PF show higher baseline levels of PD-1 and ICOS-L on tumor-infiltrating EMRA CD4+ T cells and tumor-associated macrophages, respectively; PD instead, display enhanced PD-L1 expression on TAMs, higher peripheral frequencies of proliferating Tregs at baseline and higher PD-1 levels at week 6 post-treatment initiation on CD4 and CD8 T cell subsets. Concomitant nivolumab plus definitive CRT is safe and associated with encouraging PFS rates. Further validation in the subset of locally advanced cervical cancer displaying pre-existing, adaptive immune activation is warranted.Concurrent chemoradiotherapy (CRT) with blockade of the PD-1 pathway may enhance immune-mediated tumor control through increased phagocytosis, cell death, and antigen presentation. The NiCOL phase 1 trial (NCT03298893) is designed to determine the safety/tolerance profile and the recommended phase-II dose of nivolumab with and following concurrent CRT in 16 women with locally advanced cervical cancer. Secondary endpoints include objective response rate (ORR), progression free survival (PFS), disease free survival, and immune correlates of response. Three patients experience grade 3 dose-limiting toxicities. The pre-specified endpoints are met, and overall response rate is 93.8% [95%CI: 69.8-99.8%] with a 2-year PFS of 75% [95% CI: 56.5-99.5%]. Compared to patients with progressive disease (PD), progression-free (PF) subjects show a brisker stromal immune infiltrate, higher proximity of tumor-infiltrating CD3+ T cells to PD-L1+ tumor cells and of FOXP3+ T cells to proliferating CD11c+ myeloid cells. PF show higher baseline levels of PD-1 and ICOS-L on tumor-infiltrating EMRA CD4+ T cells and tumor-associated macrophages, respectively; PD instead, display enhanced PD-L1 expression on TAMs, higher peripheral frequencies of proliferating Tregs at baseline and higher PD-1 levels at week 6 post-treatment initiation on CD4 and CD8 T cell subsets. Concomitant nivolumab plus definitive CRT is safe and associated with encouraging PFS rates. Further validation in the subset of locally advanced cervical cancer displaying pre-existing, adaptive immune activation is warranted.
Concurrent chemoradiotherapy (CRT) with blockade of the PD-1 pathway may enhance immune-mediated tumor control through increased phagocytosis, cell death, and antigen presentation. The NiCOL phase 1 trial (NCT03298893) is designed to determine the safety/tolerance profile and the recommended phase-II dose of nivolumab with and following concurrent CRT in 16 women with locally advanced cervical cancer. Secondary endpoints include objective response rate (ORR), progression free survival (PFS), disease free survival, and immune correlates of response. Three patients experience grade 3 dose-limiting toxicities. The pre-specified endpoints are met, and overall response rate is 93.8% [95%CI: 69.8–99.8%] with a 2-year PFS of 75% [95% CI: 56.5–99.5%]. Compared to patients with progressive disease (PD), progression-free (PF) subjects show a brisker stromal immune infiltrate, higher proximity of tumor-infiltrating CD3 + T cells to PD-L1 + tumor cells and of FOXP3 + T cells to proliferating CD11c + myeloid cells. PF show higher baseline levels of PD-1 and ICOS-L on tumor-infiltrating EMRA CD4 + T cells and tumor-associated macrophages, respectively; PD instead, display enhanced PD-L1 expression on TAMs, higher peripheral frequencies of proliferating Tregs at baseline and higher PD-1 levels at week 6 post-treatment initiation on CD4 and CD8 T cell subsets. Concomitant nivolumab plus definitive CRT is safe and associated with encouraging PFS rates. Further validation in the subset of locally advanced cervical cancer displaying pre-existing, adaptive immune activation is warranted.
Concurrent chemoradiotherapy (CRT) with blockade of the PD-1 pathway may enhance immune-mediated tumor control through increased phagocytosis, cell death, and antigen presentation. The NiCOL phase 1 trial (NCT03298893) is designed to determine the safety/tolerance profile and the recommended phase-II dose of nivolumab with and following concurrent CRT in 16 women with locally advanced cervical cancer. Secondary endpoints include objective response rate (ORR), progression free survival (PFS), disease free survival, and immune correlates of response. Three patients experience grade 3 dose-limiting toxicities. The pre-specified endpoints are met, and overall response rate is 93.8% [95%CI: 69.8-99.8%] with a 2-year PFS of 75% [95% CI: 56.5-99.5%]. Compared to patients with progressive disease (PD), progression-free (PF) subjects show a brisker stromal immune infiltrate, higher proximity of tumor-infiltrating CD3 T cells to PD-L1 tumor cells and of FOXP3 T cells to proliferating CD11c myeloid cells. PF show higher baseline levels of PD-1 and ICOS-L on tumor-infiltrating EMRA CD4 T cells and tumor-associated macrophages, respectively; PD instead, display enhanced PD-L1 expression on TAMs, higher peripheral frequencies of proliferating Tregs at baseline and higher PD-1 levels at week 6 post-treatment initiation on CD4 and CD8 T cell subsets. Concomitant nivolumab plus definitive CRT is safe and associated with encouraging PFS rates. Further validation in the subset of locally advanced cervical cancer displaying pre-existing, adaptive immune activation is warranted.
Concurrent chemoradiotherapy (CRT) with blockade of the PD-1 pathway may enhance immune-mediated tumor control through increased phagocytosis, cell death, and antigen presentation. The NiCOL phase 1 trial (NCT03298893) is designed to determine the safety/tolerance profile and the recommended phase-II dose of nivolumab with and following concurrent CRT in 16 women with locally advanced cervical cancer. Secondary endpoints include objective response rate (ORR), progression free survival (PFS), disease free survival, and immune correlates of response. Three patients experience grade 3 dose-limiting toxicities. The pre-specified endpoints are met, and overall response rate is 93.8% [95%CI: 69.8–99.8%] with a 2-year PFS of 75% [95% CI: 56.5–99.5%]. Compared to patients with progressive disease (PD), progression-free (PF) subjects show a brisker stromal immune infiltrate, higher proximity of tumor-infiltrating CD3+ T cells to PD-L1+ tumor cells and of FOXP3+ T cells to proliferating CD11c+ myeloid cells. PF show higher baseline levels of PD-1 and ICOS-L on tumor-infiltrating EMRA CD4+ T cells and tumor-associated macrophages, respectively; PD instead, display enhanced PD-L1 expression on TAMs, higher peripheral frequencies of proliferating Tregs at baseline and higher PD-1 levels at week 6 post-treatment initiation on CD4 and CD8 T cell subsets. Concomitant nivolumab plus definitive CRT is safe and associated with encouraging PFS rates. Further validation in the subset of locally advanced cervical cancer displaying pre-existing, adaptive immune activation is warranted.A combination of chemoradiotherapy followed by brachytherapy is recommended for patients with locally-advanced cervical cancer (LACC), however there is still a high risk of disease recurrence. Here the authors report clinical outcomes and immunologic correlates of a clinical trial of the PD-1 inhibitor nivolumab in combination with chemoradiotherapy in LACC patients.
Abstract Concurrent chemoradiotherapy (CRT) with blockade of the PD-1 pathway may enhance immune-mediated tumor control through increased phagocytosis, cell death, and antigen presentation. The NiCOL phase 1 trial (NCT03298893) is designed to determine the safety/tolerance profile and the recommended phase-II dose of nivolumab with and following concurrent CRT in 16 women with locally advanced cervical cancer. Secondary endpoints include objective response rate (ORR), progression free survival (PFS), disease free survival, and immune correlates of response. Three patients experience grade 3 dose-limiting toxicities. The pre-specified endpoints are met, and overall response rate is 93.8% [95%CI: 69.8–99.8%] with a 2-year PFS of 75% [95% CI: 56.5–99.5%]. Compared to patients with progressive disease (PD), progression-free (PF) subjects show a brisker stromal immune infiltrate, higher proximity of tumor-infiltrating CD3+ T cells to PD-L1+ tumor cells and of FOXP3+ T cells to proliferating CD11c+ myeloid cells. PF show higher baseline levels of PD-1 and ICOS-L on tumor-infiltrating EMRA CD4+ T cells and tumor-associated macrophages, respectively; PD instead, display enhanced PD-L1 expression on TAMs, higher peripheral frequencies of proliferating Tregs at baseline and higher PD-1 levels at week 6 post-treatment initiation on CD4 and CD8 T cell subsets. Concomitant nivolumab plus definitive CRT is safe and associated with encouraging PFS rates. Further validation in the subset of locally advanced cervical cancer displaying pre-existing, adaptive immune activation is warranted.
ArticleNumber 3698
Author Vacher, Sophie
Minsat, Mathieu
Lesage, Laetitia
Vanoni, Giulia
Vincent-Salomon, Anne
Meseure, Didier
Rodrigues, Manuel
Bazire, Louis
Huchet, Virginie
Pouget, Nicolas
Fourchotte, Virginie
Malhaire, Caroline
Amigorena, Sebastian
Loap, Pierre
Castel-Ajgal, Zahra
Laas, Enora
Bieche, Ivan
Marret, Gregoire
Chevrier, Marion
Champion, Laurence
Lantz, Olivier
Dubot, Coraline
Timperi, Eleonora
Servant, Nicolas
Durdux, Catherine
Lecompte, Lolita
Kamal, Maud
Romano, Emanuela
Author_xml – sequence: 1
  givenname: Manuel
  orcidid: 0000-0002-5443-0802
  surname: Rodrigues
  fullname: Rodrigues, Manuel
  organization: Department of Medical Oncology, Institut Curie
– sequence: 2
  givenname: Giulia
  surname: Vanoni
  fullname: Vanoni, Giulia
  organization: Center for Cancer Immunotherapy, INSERM U932, PSL Research University, Institut Curie
– sequence: 3
  givenname: Pierre
  surname: Loap
  fullname: Loap, Pierre
  organization: Department of Radiation Oncology, Institut Curie
– sequence: 4
  givenname: Coraline
  surname: Dubot
  fullname: Dubot, Coraline
  organization: Department of Medical Oncology, Institut Curie
– sequence: 5
  givenname: Eleonora
  orcidid: 0000-0002-8357-6587
  surname: Timperi
  fullname: Timperi, Eleonora
  organization: Center for Cancer Immunotherapy, INSERM U932, PSL Research University, Institut Curie
– sequence: 6
  givenname: Mathieu
  surname: Minsat
  fullname: Minsat, Mathieu
  organization: Department of Radiation Oncology, Institut Curie
– sequence: 7
  givenname: Louis
  surname: Bazire
  fullname: Bazire, Louis
  organization: Department of Radiation Oncology, Institut Curie
– sequence: 8
  givenname: Catherine
  surname: Durdux
  fullname: Durdux, Catherine
  organization: Hôpital Européen Georges Pompidou, Department of Radiation Oncology
– sequence: 9
  givenname: Virginie
  surname: Fourchotte
  fullname: Fourchotte, Virginie
  organization: Service of Breast and Gynecologic Surgery, Institut Curie
– sequence: 10
  givenname: Enora
  surname: Laas
  fullname: Laas, Enora
  organization: Service of Breast and Gynecologic Surgery, Institut Curie
– sequence: 11
  givenname: Nicolas
  surname: Pouget
  fullname: Pouget, Nicolas
  organization: Service of Breast and Gynecologic Surgery, Institut Curie
– sequence: 12
  givenname: Zahra
  surname: Castel-Ajgal
  fullname: Castel-Ajgal, Zahra
  organization: Department of Drug Development and Innovation, Institut Curie
– sequence: 13
  givenname: Gregoire
  surname: Marret
  fullname: Marret, Gregoire
  organization: Department of Drug Development and Innovation, Institut Curie
– sequence: 14
  givenname: Laetitia
  orcidid: 0000-0001-8592-2482
  surname: Lesage
  fullname: Lesage, Laetitia
  organization: Department of Pathology Institut Curie, Centre d’Investigation Clinique Biothérapie, Institut Curie
– sequence: 15
  givenname: Didier
  orcidid: 0000-0001-6730-6686
  surname: Meseure
  fullname: Meseure, Didier
  organization: Department of Pathology Institut Curie, Centre d’Investigation Clinique Biothérapie, Institut Curie
– sequence: 16
  givenname: Anne
  orcidid: 0000-0001-5754-5771
  surname: Vincent-Salomon
  fullname: Vincent-Salomon, Anne
  organization: Department of Pathology Institut Curie, Centre d’Investigation Clinique Biothérapie, Institut Curie
– sequence: 17
  givenname: Lolita
  orcidid: 0000-0001-8773-6317
  surname: Lecompte
  fullname: Lecompte, Lolita
  organization: Institut Curie Bioinformatics Platform, INSERM U900, Mines ParisTech
– sequence: 18
  givenname: Nicolas
  orcidid: 0000-0003-1678-7410
  surname: Servant
  fullname: Servant, Nicolas
  organization: Institut Curie Bioinformatics Platform, INSERM U900, Mines ParisTech
– sequence: 19
  givenname: Sophie
  orcidid: 0000-0002-0042-6023
  surname: Vacher
  fullname: Vacher, Sophie
  organization: Pharmacogenomics Unit, Service of Genetics, Institut Curie
– sequence: 20
  givenname: Ivan
  surname: Bieche
  fullname: Bieche, Ivan
  organization: Pharmacogenomics Unit, Service of Genetics, Institut Curie
– sequence: 21
  givenname: Caroline
  orcidid: 0000-0002-9235-9816
  surname: Malhaire
  fullname: Malhaire, Caroline
  organization: Department of Radiology, Institut Curie
– sequence: 22
  givenname: Virginie
  surname: Huchet
  fullname: Huchet, Virginie
  organization: Department of Nuclear Medicine, Institut Curie
– sequence: 23
  givenname: Laurence
  orcidid: 0000-0001-7908-5593
  surname: Champion
  fullname: Champion, Laurence
  organization: Department of Nuclear Medicine, Institut Curie
– sequence: 24
  givenname: Maud
  surname: Kamal
  fullname: Kamal, Maud
  organization: Department of Drug Development and Innovation, Institut Curie
– sequence: 25
  givenname: Sebastian
  orcidid: 0000-0001-8583-8416
  surname: Amigorena
  fullname: Amigorena, Sebastian
  organization: Center for Cancer Immunotherapy, INSERM U932, PSL Research University, Institut Curie
– sequence: 26
  givenname: Olivier
  orcidid: 0000-0003-3161-7719
  surname: Lantz
  fullname: Lantz, Olivier
  organization: Center for Cancer Immunotherapy, INSERM U932, PSL Research University, Institut Curie
– sequence: 27
  givenname: Marion
  surname: Chevrier
  fullname: Chevrier, Marion
  organization: Service of Biostatistics, Institut Curie
– sequence: 28
  givenname: Emanuela
  orcidid: 0000-0002-1574-5545
  surname: Romano
  fullname: Romano, Emanuela
  email: Emanuela.Romano@curie.fr
  organization: Department of Medical Oncology, Institut Curie, Center for Cancer Immunotherapy, INSERM U932, PSL Research University, Institut Curie
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37349318$$D View this record in MEDLINE/PubMed
BookMark eNp9kk1v1DAQhiNURD_oH-CALHHhEvBn4nBB1QrKSqv2Akdk2c5k1ysnXuxkpf33eJtS2h7qi-3x874ej-e8OBnCAEXxjuBPBDP5OXHCq7rElJWsYZKV8lVxRjEnJakpO3m0Pi0uU9riPFhDJOdvilNWM94wIs-K3zduH_zUa4N2fkrIbqAPUbcujBuIendAbkA-WO39odTtXg8WWmQh7l2OIXvcxy8ow-hmubhdod1GJ0AEjdFp_7Z43Wmf4PJ-vih-ff_2c_GjXN1eLxdXq9IKTsYSOgNCCmJw0xowpiLMVB2RhnaS08YwWwNvWUN5pSmAgJbXpOqqXAIjqGjYRbGcfdugt2oXXa_jQQXt1F0gxLXScXTWg9JAGisbsGC6rK-17VoGwlJtrWAVzV5fZ6_dZHpoLQxj1P6J6dOTwW3UOuwVwVTWFcfZ4eO9Qwx_Jkij6l2y4L0eIExJUUkbzjAWJKMfnqHbMMUh1-pISSF4JepMvX-c0kMu_74xA3QGbAwpRegeEILVsV3U3C4qt4u6axd1FMlnIutGPbpwfJbzL0vZLE35nmEN8X_aL6j-Am-Y1D8
CitedBy_id crossref_primary_10_12677_acm_2024_14123253
crossref_primary_10_3390_cancers17020202
crossref_primary_10_3390_jcm13154458
crossref_primary_10_1186_s12885_025_13843_4
crossref_primary_10_3389_fimmu_2024_1459693
crossref_primary_10_3390_diseases12040077
crossref_primary_10_1007_s12672_024_01328_y
crossref_primary_10_3389_fphar_2024_1476256
crossref_primary_10_3389_fimmu_2024_1459206
crossref_primary_10_2478_ahem_2025_0004
crossref_primary_10_1016_j_canrad_2024_09_006
crossref_primary_10_1007_s10147_025_02699_0
crossref_primary_10_1007_s00432_024_05952_7
crossref_primary_10_3389_fimmu_2024_1371559
crossref_primary_10_1016_j_intimp_2024_113268
crossref_primary_10_3389_fonc_2024_1352975
crossref_primary_10_3389_fimmu_2023_1274547
crossref_primary_10_3389_fimmu_2023_1328103
crossref_primary_10_1016_j_critrevonc_2025_104673
crossref_primary_10_1016_j_tvr_2024_200309
crossref_primary_10_1097_IO9_0000000000000059
crossref_primary_10_3389_fimmu_2024_1357601
crossref_primary_10_62347_FFXL7288
crossref_primary_10_1007_s00262_024_03823_1
crossref_primary_10_1016_S0140_6736_24_01808_7
crossref_primary_10_1093_ckj_sfad292
crossref_primary_10_12677_acm_2025_151082
crossref_primary_10_3390_biomedicines12071468
crossref_primary_10_1016_j_tjog_2024_08_001
crossref_primary_10_1080_14796694_2024_2342241
crossref_primary_10_20960_revcancer_00095
crossref_primary_10_1016_S0140_6736_24_00317_9
Cites_doi 10.1056/NEJMoa1809615
10.1016/j.chest.2017.04.177
10.1038/nature21386
10.1038/s41577-020-0306-5
10.1002/cncr.31043
10.1080/14737140.2021.1879646
10.1016/j.annonc.2021.08.1261
10.1097/IGC.0000000000001216
10.1016/j.ccell.2020.08.005
10.1016/j.ygyno.2021.08.018
10.1158/1078-0432.CCR-17-3427
10.1038/s41467-020-19288-6
10.1093/nar/gkv007
10.1038/s41467-022-33544-x
10.3322/caac.21708
10.1038/s41467-022-34676-w
10.1093/annonc/mdu450
10.1016/j.critrevonc.2018.01.003
10.1016/j.ejca.2020.09.008
10.1073/pnas.0506580102
10.1126/science.aaf1292
10.1186/s12943-019-0974-6
10.1200/JCO.18.01265
10.1016/j.immuni.2022.12.002
10.1056/NEJMoa1917338
10.1126/science.aaf0683
10.1200/JCO.20.01920
10.1056/NEJMoa2112651
10.1016/j.annonc.2021.04.009
10.1172/JCI91190
10.1056/NEJMoa2202809
10.1093/bioinformatics/btp373
10.1038/ni.2035
10.1016/j.radonc.2016.03.011
10.1016/S1470-2045(20)30737-3
10.1038/nature22079
10.15585/mmwr.mm7035a1
10.1016/j.ijrobp.2014.04.025
10.1186/1471-2105-14-7
10.1056/NEJMoa2112435
10.1056/NEJMoa1606774
10.1002/ijc.24075
10.1016/j.annonc.2020.01.072
10.1093/bioinformatics/bts635
10.18632/oncotarget.23217
10.1136/ijgc-2019-001135
10.2174/0929867327666200128105459
10.1016/j.cell.2019.01.021
10.1016/j.ydbio.2020.12.018
10.1007/s12307-012-0122-y
10.1016/j.ebiom.2019.03.069
10.1200/JCO.21.02067
10.1002/cncr.28849
10.1038/nm1093
10.1073/pnas.0408864102
10.1038/cgt.2015.40
10.1158/0008-5472.CAN-18-0163
10.1093/nar/gkq603
10.1016/j.molmed.2016.04.008
10.1093/bioinformatics/btp616
10.1200/JCO.2020.38.15_suppl.TPS6096
10.1016/S0140-6736(20)32531-9
10.1200/PO.17.00011
10.1080/2162402X.2019.1659093
10.1038/s41598-019-47910-1
10.1038/s41467-021-21736-w
10.3389/fimmu.2020.583084
10.1101/060012
10.1016/j.annonc.2022.07.646
10.1016/j.annonc.2021.08.2108
10.1182/blood-2018-99-119918
10.3389/fphar.2017.00561
10.3389/fmicb.2019.00001
10.1177/1758834017749748
ContentType Journal Article
Copyright The Author(s) 2023
2023. The Author(s).
The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2023
– notice: 2023. The Author(s).
– notice: The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7QL
7QP
7QR
7SN
7SS
7ST
7T5
7T7
7TM
7TO
7X7
7XB
88E
8AO
8FD
8FE
8FG
8FH
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
ARAPS
AZQEC
BBNVY
BENPR
BGLVJ
BHPHI
C1K
CCPQU
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
LK8
M0S
M1P
M7P
P5Z
P62
P64
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
RC3
SOI
7X8
5PM
DOA
DOI 10.1038/s41467-023-39383-8
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Bacteriology Abstracts (Microbiology B)
Calcium & Calcified Tissue Abstracts
Chemoreception Abstracts
Ecology Abstracts
Entomology Abstracts (Full archive)
Environment Abstracts
Immunology Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
Nucleic Acids Abstracts
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Technology Research Database
ProQuest SciTech Collection
ProQuest Technology Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
Advanced Technologies & Aerospace Collection
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Technology collection
Natural Science Collection (ProQuest)
Environmental Sciences and Pollution Management
ProQuest One Community College
ProQuest Central Korea
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Biological Science Collection
Health & Medical Collection (Alumni Edition)
Medical Database
Biological Science Database
Advanced Technologies & Aerospace Database
ProQuest Advanced Technologies & Aerospace Collection
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
Genetics Abstracts
Environment Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
Oncogenes and Growth Factors Abstracts
ProQuest Advanced Technologies & Aerospace Collection
ProQuest Central Essentials
Nucleic Acids Abstracts
SciTech Premium Collection
ProQuest Central China
Environmental Sciences and Pollution Management
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
Health Research Premium Collection
Natural Science Collection
Health & Medical Research Collection
Biological Science Collection
Chemoreception Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Advanced Technologies & Aerospace Collection
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
ProQuest Technology Collection
Health Research Premium Collection (Alumni)
Biological Science Database
Ecology Abstracts
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
Entomology Abstracts
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
Engineering Research Database
ProQuest One Academic
Calcium & Calcified Tissue Abstracts
ProQuest One Academic (New)
Technology Collection
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central
ProQuest Health & Medical Research Collection
Genetics Abstracts
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Bacteriology Abstracts (Microbiology B)
AIDS and Cancer Research Abstracts
ProQuest SciTech Collection
Advanced Technologies & Aerospace Database
ProQuest Medical Library
Immunology Abstracts
Environment Abstracts
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList

MEDLINE - Academic
CrossRef
MEDLINE
Publicly Available Content Database
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: 8FG
  name: ProQuest Technology Collection
  url: https://search.proquest.com/technologycollection1
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2041-1723
EndPage 15
ExternalDocumentID oai_doaj_org_article_ae19c89ecebf4147acfd3e5c2acc5362
PMC10287640
37349318
10_1038_s41467_023_39383_8
Genre Journal Article
Clinical Trial, Phase I
GrantInformation_xml – fundername: AstraZeneca
  funderid: https://doi.org/10.13039/100004325
– fundername: Bristol-Myers Squibb (Bristol-Myers Squibb Company)
  funderid: https://doi.org/10.13039/100002491
– fundername: ;
GroupedDBID ---
0R~
39C
3V.
53G
5VS
70F
7X7
88E
8AO
8FE
8FG
8FH
8FI
8FJ
AAHBH
AAJSJ
ABUWG
ACGFO
ACGFS
ACIWK
ACMJI
ACPRK
ACSMW
ADBBV
ADFRT
ADMLS
ADRAZ
AENEX
AEUYN
AFKRA
AFRAH
AHMBA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMTXH
AOIJS
ARAPS
ASPBG
AVWKF
AZFZN
BBNVY
BCNDV
BENPR
BGLVJ
BHPHI
BPHCQ
BVXVI
C6C
CCPQU
DIK
EBLON
EBS
EE.
EMOBN
F5P
FEDTE
FYUFA
GROUPED_DOAJ
HCIFZ
HMCUK
HVGLF
HYE
HZ~
KQ8
LK8
M1P
M48
M7P
M~E
NAO
O9-
OK1
P2P
P62
PIMPY
PQQKQ
PROAC
PSQYO
RNS
RNT
RNTTT
RPM
SNYQT
SV3
TSG
UKHRP
AASML
AAYXX
CITATION
PHGZM
PHGZT
CGR
CUY
CVF
ECM
EIF
NPM
7QL
7QP
7QR
7SN
7SS
7ST
7T5
7T7
7TM
7TO
7XB
8FD
8FK
AARCD
AZQEC
C1K
DWQXO
FR3
GNUQQ
H94
K9.
P64
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
PRINS
RC3
SOI
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c541t-efbe5851b09dbebb613b6f18b2f8429b3c7e4d39246a2ee5ed4716f6414b52593
IEDL.DBID M48
ISSN 2041-1723
IngestDate Wed Aug 27 01:31:23 EDT 2025
Thu Aug 21 18:36:49 EDT 2025
Fri Jul 11 07:53:50 EDT 2025
Wed Aug 13 05:15:25 EDT 2025
Wed Feb 19 02:23:00 EST 2025
Thu Apr 24 22:59:32 EDT 2025
Tue Jul 01 00:58:56 EDT 2025
Fri Feb 21 02:40:04 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License 2023. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c541t-efbe5851b09dbebb613b6f18b2f8429b3c7e4d39246a2ee5ed4716f6414b52593
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-1678-7410
0000-0002-0042-6023
0000-0002-9235-9816
0000-0002-1574-5545
0000-0001-8583-8416
0000-0001-6730-6686
0000-0001-8773-6317
0000-0002-8357-6587
0000-0001-7908-5593
0000-0003-3161-7719
0000-0002-5443-0802
0000-0001-8592-2482
0000-0001-5754-5771
OpenAccessLink https://www.nature.com/articles/s41467-023-39383-8
PMID 37349318
PQID 2828554657
PQPubID 546298
PageCount 15
ParticipantIDs doaj_primary_oai_doaj_org_article_ae19c89ecebf4147acfd3e5c2acc5362
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10287640
proquest_miscellaneous_2829430051
proquest_journals_2828554657
pubmed_primary_37349318
crossref_primary_10_1038_s41467_023_39383_8
crossref_citationtrail_10_1038_s41467_023_39383_8
springer_journals_10_1038_s41467_023_39383_8
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-06-22
PublicationDateYYYYMMDD 2023-06-22
PublicationDate_xml – month: 06
  year: 2023
  text: 2023-06-22
  day: 22
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Nature communications
PublicationTitleAbbrev Nat Commun
PublicationTitleAlternate Nat Commun
PublicationYear 2023
Publisher Nature Publishing Group UK
Nature Publishing Group
Nature Portfolio
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
– name: Nature Portfolio
References de Cremoux (CR66) 2009; 124
Reck (CR20) 2016; 375
Szulzewsky, Holland, Vasioukhin (CR45) 2021; 475
Koboldt (CR70) 2009; 25
Salgado (CR67) 2015; 26
Dobin (CR73) 2013; 29
Krishna (CR9) 2018; 78
CR39
(CR40) 2017; 543
Hänzelmann, Castelo, Guinney (CR77) 2013; 14
CR35
Chakravarthy (CR42) 2022; 13
Darragh (CR55) 2022; 13
CR76
CR31
Wherry (CR64) 2011; 12
Huang (CR65) 2017; 545
CR72
Zhang (CR10) 2021; 28
Lan (CR17) 2020; 38
Ayers (CR34) 2017; 127
Cortes (CR22) 2020; 396
Pal, Kundu (CR2) 2019; 10
O’Malley (CR14) 2021; 163
Grasso (CR33) 2020; 38
CR48
CR47
Cortes (CR52) 2022; 387
Cibula (CR5) 2018; 28
Pingali (CR4) 2021; 70
Ray-Coquard (CR54) 2021; 32
Kamphorst (CR59) 2017; 355
Kang, Bader, Vogt (CR44) 2005; 102
Diehl, Yarchoan, Hopkins, Jaffee, Grossman (CR32) 2017; 8
Venkatesulu, Mallick, Lin, Krishnan (CR27) 2018; 123
Tanchot (CR61) 2013; 6
Tang (CR28) 2014; 89
Yi (CR46) 2019; 18
Prokhnevska (CR57) 2023; 56
Schmid (CR51) 2022; 386
Ritchie (CR75) 2015; 43
CR15
Chung (CR16) 2019; 37
CR58
Schmid (CR21) 2018; 379
Lorusso (CR53) 2020; 38
Hamarsheh, Groß, Brummer, Zeiser (CR38) 2020; 11
Pillai (CR50) 2018; 124
Siegel, Miller, Fuchs, Jemal (CR1) 2022; 72
Khunger (CR49) 2017; 152
Robinson, McCarthy, Smyth (CR74) 2010; 26
Lee (CR30) 2021; 22
Wang, Li, Hakonarson (CR71) 2010; 38
O’Malley (CR18) 2022; 40
Chen (CR43) 2019; 12
Rice (CR11) 2015; 22
Scholl (CR41) 2019; 43
Marciscano (CR56) 2018; 24
Colombo (CR12) 2021; 385
Viswanathan (CR26) 2014; 120
Lei (CR3) 2020; 383
Gennigens, de Cuypere, Hermesse, Kridelka, Jerusalem (CR6) 2021; 21
Sturdza (CR7) 2016; 120
CR25
CR69
Schmid (CR23) 2020; 31
CR24
Hui (CR60) 2017; 355
CR68
Bu, Mahoney, Freeman (CR36) 2016; 22
Apte, Chen, Ferrara (CR37) 2019; 176
CR63
Tewari (CR13) 2021; 32
Mayadev (CR19) 2020; 30
Tao (CR29) 2020; 141
Curiel (CR62) 2004; 10
Waldman, Fritz, Lenardo (CR8) 2020; 20
Subramanian (CR78) 2005; 102
A Subramanian (39383_CR78) 2005; 102
CS Grasso (39383_CR33) 2020; 38
L Zhang (39383_CR10) 2021; 28
J Cortes (39383_CR52) 2022; 387
TJ Curiel (39383_CR62) 2004; 10
S Krishna (39383_CR9) 2018; 78
D Lorusso (39383_CR53) 2020; 38
RS Apte (39383_CR37) 2019; 176
M Reck (39383_CR20) 2016; 375
LB Darragh (39383_CR55) 2022; 13
39383_CR58
39383_CR15
AC Huang (39383_CR65) 2017; 545
MD Robinson (39383_CR74) 2010; 26
A Pal (39383_CR2) 2019; 10
F Szulzewsky (39383_CR45) 2021; 475
Cancer Genome Atlas Research Network. (39383_CR40) 2017; 543
HC Chung (39383_CR16) 2019; 37
AN Viswanathan (39383_CR26) 2014; 120
DM O’Malley (39383_CR18) 2022; 40
RN Pillai (39383_CR50) 2018; 124
R Salgado (39383_CR67) 2015; 26
S Scholl (39383_CR41) 2019; 43
S Hänzelmann (39383_CR77) 2013; 14
AD Waldman (39383_CR8) 2020; 20
A Chakravarthy (39383_CR42) 2022; 13
E Hui (39383_CR60) 2017; 355
39383_CR47
K Wang (39383_CR71) 2010; 38
Y Tao (39383_CR29) 2020; 141
39383_CR48
DC Koboldt (39383_CR70) 2009; 25
X Bu (39383_CR36) 2016; 22
M Chen (39383_CR43) 2019; 12
N Prokhnevska (39383_CR57) 2023; 56
ME Ritchie (39383_CR75) 2015; 43
J Mayadev (39383_CR19) 2020; 30
M Ayers (39383_CR34) 2017; 127
P Schmid (39383_CR51) 2022; 386
P de Cremoux (39383_CR66) 2009; 124
IL Ray-Coquard (39383_CR54) 2021; 32
C Tanchot (39383_CR61) 2013; 6
C Lan (39383_CR17) 2020; 38
BP Venkatesulu (39383_CR27) 2018; 123
C Tang (39383_CR28) 2014; 89
C Pingali (39383_CR4) 2021; 70
J Lei (39383_CR3) 2020; 383
AO Kamphorst (39383_CR59) 2017; 355
39383_CR35
S Hamarsheh (39383_CR38) 2020; 11
A Dobin (39383_CR73) 2013; 29
N Colombo (39383_CR12) 2021; 385
39383_CR39
C Gennigens (39383_CR6) 2021; 21
AE Marciscano (39383_CR56) 2018; 24
P Schmid (39383_CR23) 2020; 31
J Cortes (39383_CR22) 2020; 396
39383_CR72
39383_CR31
39383_CR76
AE Rice (39383_CR11) 2015; 22
A Diehl (39383_CR32) 2017; 8
P Schmid (39383_CR21) 2018; 379
S Kang (39383_CR44) 2005; 102
RL Siegel (39383_CR1) 2022; 72
D Cibula (39383_CR5) 2018; 28
M Yi (39383_CR46) 2019; 18
39383_CR24
39383_CR68
KS Tewari (39383_CR13) 2021; 32
39383_CR25
39383_CR69
M Khunger (39383_CR49) 2017; 152
NY Lee (39383_CR30) 2021; 22
EJ Wherry (39383_CR64) 2011; 12
A Sturdza (39383_CR7) 2016; 120
DM O’Malley (39383_CR14) 2021; 163
39383_CR63
References_xml – volume: 379
  start-page: 2108
  year: 2018
  end-page: 2121
  ident: CR21
  article-title: Atezolizumab and Nab-paclitaxel in advanced triple-negative breast cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1809615
– volume: 152
  start-page: 271
  year: 2017
  end-page: 281
  ident: CR49
  article-title: Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer
  publication-title: Chest
  doi: 10.1016/j.chest.2017.04.177
– volume: 543
  start-page: 378
  year: 2017
  end-page: 384
  ident: CR40
  article-title: Integrated genomic and molecular characterization of cervical cancer
  publication-title: Nature
  doi: 10.1038/nature21386
– volume: 20
  start-page: 651
  year: 2020
  end-page: 668
  ident: CR8
  article-title: A guide to cancer immunotherapy: from T cell basic science to clinical practice
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/s41577-020-0306-5
– ident: CR68
– volume: 124
  start-page: 271
  year: 2018
  end-page: 277
  ident: CR50
  article-title: Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: a systematic analysis of the literature
  publication-title: Cancer
  doi: 10.1002/cncr.31043
– volume: 21
  start-page: 657
  year: 2021
  end-page: 671
  ident: CR6
  article-title: Optimal treatment in locally advanced cervical cancer
  publication-title: Expert Rev. Anticancer Ther.
  doi: 10.1080/14737140.2021.1879646
– ident: CR39
– volume: 32
  start-page: S770
  year: 2021
  ident: CR54
  article-title: 819TiP COLIBRI trial (GINECO-CE108b): a multicenter, window study evaluating immune impact and safety of nivolumab in combination with ipilimumab before initial radio-chemotherapy (RTCT) treatment for locally advanced cervix cancer
  publication-title: Ann. Oncol.
  doi: 10.1016/j.annonc.2021.08.1261
– volume: 28
  start-page: 641
  year: 2018
  end-page: 655
  ident: CR5
  article-title: The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the management of patients with cervical cancer
  publication-title: Int. J. Gynecol. Cancer
  doi: 10.1097/IGC.0000000000001216
– volume: 38
  start-page: 500
  year: 2020
  end-page: 515.e3
  ident: CR33
  article-title: Conserved interferon-γ signaling drives clinical response to immune checkpoint blockade therapy in melanoma
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2020.08.005
– volume: 163
  start-page: 274
  year: 2021
  end-page: 280
  ident: CR14
  article-title: Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer
  publication-title: Gynecol. Oncol.
  doi: 10.1016/j.ygyno.2021.08.018
– volume: 24
  start-page: 5058
  year: 2018
  end-page: 5071
  ident: CR56
  article-title: Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-17-3427
– volume: 11
  year: 2020
  ident: CR38
  article-title: Immune modulatory effects of oncogenic KRAS in cancer
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-19288-6
– volume: 43
  start-page: e47
  year: 2015
  ident: CR75
  article-title: limma powers differential expression analyses for RNA-sequencing and microarray studies
  publication-title: Nucleic Acids Res.
  doi: 10.1093/nar/gkv007
– volume: 13
  year: 2022
  ident: CR42
  article-title: Integrated analysis of cervical squamous cell carcinoma cohorts from three continents reveals conserved subtypes of prognostic significance
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-022-33544-x
– ident: CR35
– volume: 72
  start-page: 7
  year: 2022
  end-page: 33
  ident: CR1
  article-title: Cancer statistics, 2022
  publication-title: CA Cancer J. Clin.
  doi: 10.3322/caac.21708
– volume: 13
  year: 2022
  ident: CR55
  article-title: Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-022-34676-w
– ident: CR58
– volume: 26
  start-page: 259
  year: 2015
  end-page: 271
  ident: CR67
  article-title: The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdu450
– ident: CR25
– volume: 123
  start-page: 42
  year: 2018
  end-page: 51
  ident: CR27
  article-title: A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors
  publication-title: Crit. Rev. Oncol. Hematol.
  doi: 10.1016/j.critrevonc.2018.01.003
– volume: 141
  start-page: 21
  year: 2020
  end-page: 29
  ident: CR29
  article-title: Avelumab–cetuximab–radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: the safety phase of a randomised phase III trial GORTEC 2017-01 (REACH)
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2020.09.008
– volume: 102
  start-page: 15545
  year: 2005
  end-page: 15550
  ident: CR78
  article-title: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.0506580102
– volume: 10
  start-page: 1
  year: 2019
  end-page: 15
  ident: CR2
  article-title: Human papillomavirus E6 and E7: the cervical cancer hallmarks and targets for therapy
  publication-title: Front. Microbiol.
– volume: 355
  start-page: 1428
  year: 2017
  end-page: 1433
  ident: CR60
  article-title: T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
  publication-title: Science
  doi: 10.1126/science.aaf1292
– volume: 18
  year: 2019
  ident: CR46
  article-title: Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
  publication-title: Mol. Cancer
  doi: 10.1186/s12943-019-0974-6
– volume: 37
  start-page: 1470
  year: 2019
  end-page: 1478
  ident: CR16
  article-title: Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 Study
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.18.01265
– volume: 56
  start-page: 107
  year: 2023
  end-page: 124.e5
  ident: CR57
  article-title: CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor
  publication-title: Immunity
  doi: 10.1016/j.immuni.2022.12.002
– volume: 383
  start-page: 1340
  year: 2020
  end-page: 1348
  ident: CR3
  article-title: HPV vaccination and the risk of invasive cervical cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1917338
– volume: 355
  start-page: 1423
  year: 2017
  end-page: 1427
  ident: CR59
  article-title: Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
  publication-title: Science
  doi: 10.1126/science.aaf0683
– ident: CR15
– volume: 38
  start-page: 4095
  year: 2020
  end-page: 4106
  ident: CR17
  article-title: Camrelizumab plus apatinib in patients with advanced cervical cancer (CLAP): a multicenter, open-label, single-arm, phase II trial
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.20.01920
– volume: 386
  start-page: 556
  year: 2022
  end-page: 567
  ident: CR51
  article-title: Event-free survival with pembrolizumab in early triple-negative breast cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2112651
– volume: 12
  start-page: 3807
  year: 2019
  end-page: 3818
  ident: CR43
  article-title: FAT1 inhibits the proliferation and metastasis of cervical cancer cells by binding β-catenin
  publication-title: Int. J. Clin. Exp. Pathol.
– volume: 32
  start-page: 940
  year: 2021
  end-page: 941
  ident: CR13
  article-title: VP4-2021: EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: interim analysis of phase III trial of cemiplimab vs. investigator’s choice (IC) chemotherapy (chemo) in recurrent/metastatic (R/M) cervical carcinoma
  publication-title: Ann. Oncol.
  doi: 10.1016/j.annonc.2021.04.009
– volume: 127
  start-page: 2930
  year: 2017
  end-page: 2940
  ident: CR34
  article-title: IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI91190
– volume: 387
  start-page: 217
  year: 2022
  end-page: 226
  ident: CR52
  article-title: Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2202809
– volume: 25
  start-page: 2283
  year: 2009
  end-page: 2285
  ident: CR70
  article-title: VarScan: variant detection in massively parallel sequencing of individual and pooled samples
  publication-title: Bioinformatics
  doi: 10.1093/bioinformatics/btp373
– ident: CR47
– volume: 12
  start-page: 492
  year: 2011
  end-page: 499
  ident: CR64
  article-title: T cell exhaustion
  publication-title: Nat. Immunol.
  doi: 10.1038/ni.2035
– ident: CR72
– volume: 120
  start-page: 428
  year: 2016
  end-page: 433
  ident: CR7
  article-title: Image guided brachytherapy in locally advanced cervical cancer: improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study
  publication-title: Radiother. Oncol.
  doi: 10.1016/j.radonc.2016.03.011
– volume: 22
  start-page: 450
  year: 2021
  end-page: 462
  ident: CR30
  article-title: Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(20)30737-3
– volume: 545
  start-page: 60
  year: 2017
  end-page: 65
  ident: CR65
  article-title: T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
  publication-title: Nature
  doi: 10.1038/nature22079
– volume: 70
  start-page: 1183
  year: 2021
  end-page: 1190
  ident: CR4
  article-title: National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 Years - United States, 2020
  publication-title: MMWR Morb. Mortal. Wkly Rep.
  doi: 10.15585/mmwr.mm7035a1
– volume: 89
  start-page: 1084
  year: 2014
  end-page: 1091
  ident: CR28
  article-title: Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes
  publication-title: Int. J. Radiat. Oncol. Biol. Phys.
  doi: 10.1016/j.ijrobp.2014.04.025
– volume: 14
  year: 2013
  ident: CR77
  article-title: GSVA: gene set variation analysis for microarray and RNA-Seq data
  publication-title: BMC Bioinformatcs
  doi: 10.1186/1471-2105-14-7
– ident: CR63
– volume: 385
  start-page: 1856
  year: 2021
  end-page: 1867
  ident: CR12
  article-title: Pembrolizumab for persistent, recurrent, or metastatic cervical cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2112435
– volume: 375
  start-page: 1823
  year: 2016
  end-page: 1833
  ident: CR20
  article-title: Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1606774
– volume: 124
  start-page: 778
  year: 2009
  end-page: 782
  ident: CR66
  article-title: Different outcome of invasive cervical cancer associated with high-risk versus intermediate-risk HPV genotype
  publication-title: Int. J. Cancer
  doi: 10.1002/ijc.24075
– volume: 31
  start-page: 569
  year: 2020
  end-page: 581
  ident: CR23
  article-title: Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
  publication-title: Ann. Oncol.
  doi: 10.1016/j.annonc.2020.01.072
– ident: CR69
– volume: 29
  start-page: 15
  year: 2013
  end-page: 21
  ident: CR73
  article-title: STAR: ultrafast universal RNA-seq aligner
  publication-title: Bioinformatics
  doi: 10.1093/bioinformatics/bts635
– volume: 8
  start-page: 114268
  year: 2017
  end-page: 114280
  ident: CR32
  article-title: Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.23217
– ident: CR48
– volume: 30
  start-page: 1065
  year: 2020
  end-page: 1070
  ident: CR19
  article-title: CALLA: efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study
  publication-title: Int. J. Gynecol. Cancer
  doi: 10.1136/ijgc-2019-001135
– volume: 28
  start-page: 893
  year: 2021
  end-page: 909
  ident: CR10
  article-title: The roles of programmed cell death ligand-1/ programmed cell death-1 (PD-L1/PD-1) in HPV-induced cervical cancer and potential for their use in blockade therapy
  publication-title: Curr. Med. Chem.
  doi: 10.2174/0929867327666200128105459
– volume: 176
  start-page: 1248
  year: 2019
  end-page: 1264
  ident: CR37
  article-title: VEGF in signaling and disease: beyond discovery and development
  publication-title: Cell
  doi: 10.1016/j.cell.2019.01.021
– volume: 475
  start-page: 205
  year: 2021
  end-page: 221
  ident: CR45
  article-title: YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance
  publication-title: Dev. Biol.
  doi: 10.1016/j.ydbio.2020.12.018
– volume: 6
  start-page: 147
  year: 2013
  end-page: 157
  ident: CR61
  article-title: Tumor-infiltrating regulatory T cells: phenotype, role, mechanism of expansion in situ and clinical significance
  publication-title: Cancer Microenviron.
  doi: 10.1007/s12307-012-0122-y
– volume: 43
  start-page: 253
  year: 2019
  end-page: 260
  ident: CR41
  article-title: Clinical and genetic landscape of treatment naive cervical cancer: alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome
  publication-title: EBioMedicine
  doi: 10.1016/j.ebiom.2019.03.069
– volume: 40
  start-page: 762
  year: 2022
  end-page: 771
  ident: CR18
  article-title: Dual PD-1 and CTLA-4 checkpoint blockade using balstilimab and zalifrelimab combination as second-line treatment for advanced cervical cancer: an open-label phase II study
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.21.02067
– volume: 120
  start-page: 3870
  year: 2014
  end-page: 3883
  ident: CR26
  article-title: Complications of pelvic radiation in patients treated for gynecologic malignancies
  publication-title: Cancer
  doi: 10.1002/cncr.28849
– ident: CR31
– volume: 10
  start-page: 942
  year: 2004
  end-page: 949
  ident: CR62
  article-title: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
  publication-title: Nat. Med.
  doi: 10.1038/nm1093
– volume: 102
  start-page: 802
  year: 2005
  end-page: 807
  ident: CR44
  article-title: Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.0408864102
– volume: 22
  start-page: 454
  year: 2015
  end-page: 462
  ident: CR11
  article-title: An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression
  publication-title: Cancer Gene Ther.
  doi: 10.1038/cgt.2015.40
– volume: 78
  start-page: 6159
  year: 2018
  end-page: 6170
  ident: CR9
  article-title: Human papilloma virus specific immunogenicity and dysfunction of CD8+ T cells in head and neck cancer
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-18-0163
– volume: 38
  start-page: e164
  year: 2010
  end-page: e164
  ident: CR71
  article-title: ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
  publication-title: Nucleic Acids Res.
  doi: 10.1093/nar/gkq603
– ident: CR76
– volume: 22
  start-page: 448
  year: 2016
  end-page: 451
  ident: CR36
  article-title: Learning from PD-1 resistance: new combination strategies
  publication-title: Trends Mol. Med.
  doi: 10.1016/j.molmed.2016.04.008
– volume: 26
  start-page: 139
  year: 2010
  end-page: 140
  ident: CR74
  article-title: edgeR: a bioconductor package for differential expression analysis of digital gene expression data
  publication-title: Bioinformatics
  doi: 10.1093/bioinformatics/btp616
– volume: 38
  start-page: TPS6096
  year: 2020
  ident: CR53
  article-title: ENGOT-cx11/KEYNOTE-A18: a phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2020.38.15_suppl.TPS6096
– ident: CR24
– volume: 396
  start-page: 1817
  year: 2020
  end-page: 1828
  ident: CR22
  article-title: Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)32531-9
– volume: 120
  start-page: 3870
  year: 2014
  ident: 39383_CR26
  publication-title: Cancer
  doi: 10.1002/cncr.28849
– volume: 12
  start-page: 3807
  year: 2019
  ident: 39383_CR43
  publication-title: Int. J. Clin. Exp. Pathol.
– volume: 28
  start-page: 893
  year: 2021
  ident: 39383_CR10
  publication-title: Curr. Med. Chem.
  doi: 10.2174/0929867327666200128105459
– volume: 30
  start-page: 1065
  year: 2020
  ident: 39383_CR19
  publication-title: Int. J. Gynecol. Cancer
  doi: 10.1136/ijgc-2019-001135
– volume: 72
  start-page: 7
  year: 2022
  ident: 39383_CR1
  publication-title: CA Cancer J. Clin.
  doi: 10.3322/caac.21708
– volume: 37
  start-page: 1470
  year: 2019
  ident: 39383_CR16
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.18.01265
– ident: 39383_CR72
– volume: 26
  start-page: 259
  year: 2015
  ident: 39383_CR67
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdu450
– volume: 32
  start-page: 940
  year: 2021
  ident: 39383_CR13
  publication-title: Ann. Oncol.
  doi: 10.1016/j.annonc.2021.04.009
– volume: 475
  start-page: 205
  year: 2021
  ident: 39383_CR45
  publication-title: Dev. Biol.
  doi: 10.1016/j.ydbio.2020.12.018
– ident: 39383_CR69
  doi: 10.1200/PO.17.00011
– volume: 20
  start-page: 651
  year: 2020
  ident: 39383_CR8
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/s41577-020-0306-5
– volume: 31
  start-page: 569
  year: 2020
  ident: 39383_CR23
  publication-title: Ann. Oncol.
  doi: 10.1016/j.annonc.2020.01.072
– volume: 141
  start-page: 21
  year: 2020
  ident: 39383_CR29
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2020.09.008
– volume: 8
  start-page: 114268
  year: 2017
  ident: 39383_CR32
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.23217
– volume: 123
  start-page: 42
  year: 2018
  ident: 39383_CR27
  publication-title: Crit. Rev. Oncol. Hematol.
  doi: 10.1016/j.critrevonc.2018.01.003
– volume: 11
  year: 2020
  ident: 39383_CR38
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-19288-6
– volume: 32
  start-page: S770
  year: 2021
  ident: 39383_CR54
  publication-title: Ann. Oncol.
  doi: 10.1016/j.annonc.2021.08.1261
– volume: 13
  year: 2022
  ident: 39383_CR55
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-022-34676-w
– ident: 39383_CR24
  doi: 10.1080/2162402X.2019.1659093
– volume: 43
  start-page: 253
  year: 2019
  ident: 39383_CR41
  publication-title: EBioMedicine
  doi: 10.1016/j.ebiom.2019.03.069
– volume: 22
  start-page: 450
  year: 2021
  ident: 39383_CR30
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(20)30737-3
– ident: 39383_CR48
  doi: 10.1038/s41598-019-47910-1
– volume: 18
  year: 2019
  ident: 39383_CR46
  publication-title: Mol. Cancer
  doi: 10.1186/s12943-019-0974-6
– volume: 124
  start-page: 778
  year: 2009
  ident: 39383_CR66
  publication-title: Int. J. Cancer
  doi: 10.1002/ijc.24075
– ident: 39383_CR25
– ident: 39383_CR39
  doi: 10.1038/s41467-021-21736-w
– ident: 39383_CR63
  doi: 10.3389/fimmu.2020.583084
– volume: 355
  start-page: 1428
  year: 2017
  ident: 39383_CR60
  publication-title: Science
  doi: 10.1126/science.aaf1292
– volume: 38
  start-page: 4095
  year: 2020
  ident: 39383_CR17
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.20.01920
– ident: 39383_CR76
  doi: 10.1101/060012
– volume: 396
  start-page: 1817
  year: 2020
  ident: 39383_CR22
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)32531-9
– ident: 39383_CR15
  doi: 10.1016/j.annonc.2022.07.646
– volume: 387
  start-page: 217
  year: 2022
  ident: 39383_CR52
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2202809
– ident: 39383_CR58
  doi: 10.1016/j.annonc.2021.08.2108
– volume: 10
  start-page: 942
  year: 2004
  ident: 39383_CR62
  publication-title: Nat. Med.
  doi: 10.1038/nm1093
– volume: 89
  start-page: 1084
  year: 2014
  ident: 39383_CR28
  publication-title: Int. J. Radiat. Oncol. Biol. Phys.
  doi: 10.1016/j.ijrobp.2014.04.025
– volume: 25
  start-page: 2283
  year: 2009
  ident: 39383_CR70
  publication-title: Bioinformatics
  doi: 10.1093/bioinformatics/btp373
– volume: 22
  start-page: 448
  year: 2016
  ident: 39383_CR36
  publication-title: Trends Mol. Med.
  doi: 10.1016/j.molmed.2016.04.008
– volume: 24
  start-page: 5058
  year: 2018
  ident: 39383_CR56
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-17-3427
– volume: 28
  start-page: 641
  year: 2018
  ident: 39383_CR5
  publication-title: Int. J. Gynecol. Cancer
  doi: 10.1097/IGC.0000000000001216
– volume: 14
  year: 2013
  ident: 39383_CR77
  publication-title: BMC Bioinformatcs
  doi: 10.1186/1471-2105-14-7
– volume: 6
  start-page: 147
  year: 2013
  ident: 39383_CR61
  publication-title: Cancer Microenviron.
  doi: 10.1007/s12307-012-0122-y
– volume: 102
  start-page: 15545
  year: 2005
  ident: 39383_CR78
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.0506580102
– volume: 29
  start-page: 15
  year: 2013
  ident: 39383_CR73
  publication-title: Bioinformatics
  doi: 10.1093/bioinformatics/bts635
– volume: 383
  start-page: 1340
  year: 2020
  ident: 39383_CR3
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1917338
– volume: 176
  start-page: 1248
  year: 2019
  ident: 39383_CR37
  publication-title: Cell
  doi: 10.1016/j.cell.2019.01.021
– volume: 120
  start-page: 428
  year: 2016
  ident: 39383_CR7
  publication-title: Radiother. Oncol.
  doi: 10.1016/j.radonc.2016.03.011
– volume: 38
  start-page: 500
  year: 2020
  ident: 39383_CR33
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2020.08.005
– volume: 385
  start-page: 1856
  year: 2021
  ident: 39383_CR12
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2112435
– volume: 21
  start-page: 657
  year: 2021
  ident: 39383_CR6
  publication-title: Expert Rev. Anticancer Ther.
  doi: 10.1080/14737140.2021.1879646
– volume: 152
  start-page: 271
  year: 2017
  ident: 39383_CR49
  publication-title: Chest
  doi: 10.1016/j.chest.2017.04.177
– volume: 375
  start-page: 1823
  year: 2016
  ident: 39383_CR20
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1606774
– volume: 56
  start-page: 107
  year: 2023
  ident: 39383_CR57
  publication-title: Immunity
  doi: 10.1016/j.immuni.2022.12.002
– volume: 13
  year: 2022
  ident: 39383_CR42
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-022-33544-x
– volume: 545
  start-page: 60
  year: 2017
  ident: 39383_CR65
  publication-title: Nature
  doi: 10.1038/nature22079
– volume: 355
  start-page: 1423
  year: 2017
  ident: 39383_CR59
  publication-title: Science
  doi: 10.1126/science.aaf0683
– volume: 40
  start-page: 762
  year: 2022
  ident: 39383_CR18
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.21.02067
– volume: 386
  start-page: 556
  year: 2022
  ident: 39383_CR51
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2112651
– volume: 38
  start-page: TPS6096
  year: 2020
  ident: 39383_CR53
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2020.38.15_suppl.TPS6096
– volume: 78
  start-page: 6159
  year: 2018
  ident: 39383_CR9
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-18-0163
– ident: 39383_CR31
  doi: 10.1182/blood-2018-99-119918
– volume: 543
  start-page: 378
  year: 2017
  ident: 39383_CR40
  publication-title: Nature
  doi: 10.1038/nature21386
– volume: 38
  start-page: e164
  year: 2010
  ident: 39383_CR71
  publication-title: Nucleic Acids Res.
  doi: 10.1093/nar/gkq603
– volume: 12
  start-page: 492
  year: 2011
  ident: 39383_CR64
  publication-title: Nat. Immunol.
  doi: 10.1038/ni.2035
– volume: 43
  start-page: e47
  year: 2015
  ident: 39383_CR75
  publication-title: Nucleic Acids Res.
  doi: 10.1093/nar/gkv007
– volume: 163
  start-page: 274
  year: 2021
  ident: 39383_CR14
  publication-title: Gynecol. Oncol.
  doi: 10.1016/j.ygyno.2021.08.018
– ident: 39383_CR47
  doi: 10.3389/fphar.2017.00561
– volume: 124
  start-page: 271
  year: 2018
  ident: 39383_CR50
  publication-title: Cancer
  doi: 10.1002/cncr.31043
– volume: 102
  start-page: 802
  year: 2005
  ident: 39383_CR44
  publication-title: Proc. Natl Acad. Sci. USA
  doi: 10.1073/pnas.0408864102
– volume: 22
  start-page: 454
  year: 2015
  ident: 39383_CR11
  publication-title: Cancer Gene Ther.
  doi: 10.1038/cgt.2015.40
– volume: 26
  start-page: 139
  year: 2010
  ident: 39383_CR74
  publication-title: Bioinformatics
  doi: 10.1093/bioinformatics/btp616
– volume: 127
  start-page: 2930
  year: 2017
  ident: 39383_CR34
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI91190
– volume: 10
  start-page: 1
  year: 2019
  ident: 39383_CR2
  publication-title: Front. Microbiol.
  doi: 10.3389/fmicb.2019.00001
– volume: 70
  start-page: 1183
  year: 2021
  ident: 39383_CR4
  publication-title: MMWR Morb. Mortal. Wkly Rep.
  doi: 10.15585/mmwr.mm7035a1
– ident: 39383_CR35
  doi: 10.1177/1758834017749748
– ident: 39383_CR68
– volume: 379
  start-page: 2108
  year: 2018
  ident: 39383_CR21
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1809615
SSID ssj0000391844
Score 2.5507705
Snippet Concurrent chemoradiotherapy (CRT) with blockade of the PD-1 pathway may enhance immune-mediated tumor control through increased phagocytosis, cell death, and...
Abstract Concurrent chemoradiotherapy (CRT) with blockade of the PD-1 pathway may enhance immune-mediated tumor control through increased phagocytosis, cell...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 3698
SubjectTerms 13/31
13/51
38
45
45/23
631/67/580
692/4028/67/1517/1371
692/53/2423
Antigen presentation
Antigens
B7-H1 Antigen
Brachytherapy
Cancer
CD11c antigen
CD3 antigen
CD4 antigen
CD8 antigen
Cell death
Cervical cancer
Chemoradiotherapy
Chemotherapy
Female
Foxp3 protein
Health risks
Humanities and Social Sciences
Humans
Immunological tolerance
Immunotherapy
Lung Neoplasms - drug therapy
Lymphocytes
Lymphocytes T
Macrophages
Monoclonal antibodies
multidisciplinary
Myeloid cells
Nivolumab - therapeutic use
Patients
PD-1 protein
PD-L1 protein
Phagocytosis
Programmed Cell Death 1 Receptor
Radiation therapy
Response rates
Risk assessment
Science
Science (multidisciplinary)
Survival
Targeted cancer therapy
Tumor cells
Tumors
Uterine Cervical Neoplasms - drug therapy
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQJSQuiDeBgozEDawmfru3UlEVBMuFSr0gy3Ym6krbdNXdPey_Z-xkly7PC8fETjSa1zcjj2cIeS1b0SqTJLMAhsnOcBajw2RF5JqLoKOp8-XkzxN9eiY_nqvzG6O-ck3Y0B54YNxBgMYl6yBB7GQjTUhdK0AlHlJSo_dFzLuRTBUfLBymLnK8JVMLe7CQxScgRDHhMC1jdgeJSsP-30WZvxZL_nRiWoDo5B65O0aQ9Gig_D65Bf0DcnuYKbl-SL5NpsXjhEjns9WColAuUcztdLxqtabTnhYEm63ZpgKApuIy8LcpP18fUtxMJx-Ov3yi8wsEOtrQMt_jETk7ef_1-JSNMxRYUrJZMugi5JO_WLs2QoyI3lF3jY28swhFUSQDKC_MwnTgAApaRCvdaeRWVJgaicdkr7_q4Smhug081RLD8Zik0NqKFNogogtKAndNRZoNP30aG4znORczXw66hfWDDDzKwBcZeFuRN9tv5kN7jb_ufpfFtN2ZW2OXF6gwflQY_y-Fqcj-Rsh-tNeFz4lnrtdTpiKvtstoafn4JPRwtSp7cq969GIVeTLoxJYSYYR06B4rYne0ZYfU3ZV-elG6eecIz2hZV-TtRrF-0PVnXjz7H7x4Tu7wbBG1Zpzvk73l9QpeYJC1jC-LPX0HAJwj1g
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lj9MwEB7BIiQuiDdZFmQkbmBtEju2wwXBitWCoFxYqRdk2Y7DVippt49D_z1jx8mqPPbYxo1cf-P5ZjzjGYBXvGFNJR2nyntJeStLam2NzgoLORdGWJmHy8lfJ-LsnH-eVtN04LZOaZWDToyKulm4cEZ-HFyDkFFVyXfLSxq6RoXoamqhcRNuhdJlIaVLTuV4xhKqnyvO012ZnKnjNY-aAYmKshqdM6r2-CiW7f-Xrfl3yuQfcdNIR6f34G6yI8n7Hvj7cMN3D-B231ly9xB-TGZR7xhLlvPtmiA0vxDsZpYuXO3IrCORx-Y7OuQBEBcVB77Whc-rtwQHk8mnk29fyPIC6Y4UJHb5eATnpx-_n5zR1EmBuooXG-pb60P8z-Z1Y721yOFWtIWyZauQkCxz0iNq6IsJU3pf-QY5S7QCV8tW6CCxx3DQLTr_FIhoTOlyjka5dZwJoZgzjWG2NhX3ZV1kUAzrqV0qMx66Xcx1DHczpXsMNGKgIwZaZfB6_M2yL7Jx7egPAaZxZCiQHb9YrH7qtN-08UXtVO2dty2-QRrXNsxXrjTOVUjaGRwNIOu0a9f6SsYyeDk-xv0Wgiim84ttHBMq1qMuy-BJLxPjTJhkvEYlmYHak5a9qe4_6WYXsaZ3sPOk4HkGbwbBuprX_9fi8Pq_8QzulEHWc0HL8ggONqutf45G1Ma-iDvlNz53GXk
  priority: 102
  providerName: ProQuest
– databaseName: Springer Nature OA Free Journals
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB6VIiQuiPIMtJWRuIFF4lccbrCiKgiWC5V6QZbtOHSlJbvax2H_PWPngRYKUo9JJpHlGc83kxl_Bngpal7L0guqQyipaEpGnaswWeGx58IqV-Zxc_KXqTq_EJ8u5eUBsGEvTGraT5SWyU0P3WFv1iItaUQYyivMqqi-BbcjdXu06omajP9VIuO5FqLfH5Nzfc2rexiUqPqviy__bpP8o1aaIOjsPtzrY0fyrhvtERyE9gHc6U6T3D2E79NZ8jXWkeV8uyaojp-o4HrWb7LakVlLEnbNd3So_ROfnAV-1sfr1VuCwmT6cfL1M1leIcSRgqSTPR7BxdmHb5Nz2p-eQL0UxYaGxoVY83N5VbvgHOK2U02hHWs0gpDjvgyoKcy_lGUhyFAjTqlG4Ww5iUkRfwyH7aINT4Go2jKfCwzEnRdcKc29rS13lZUisKrIoBjm0_ieWjyecDE3qcTNtel0YFAHJunA6Axeje8sO2KN_0q_j2oaJSMpdrqxWP0wvZEYG4rK6yr44Br8Qml9U_MgPbPeSwTqDI4HJZt-pa5NTDljp54sM3gxPsY1Fgsntg2LbZKJLPXovzJ40tnEOBJeclGhY8xA71nL3lD3n7Szq8TjHWO7Uok8g9eDYf0e17_n4tnNxJ_DXRZtP1eUsWM43Ky24QQDqY07TSvnF35xFz8
  priority: 102
  providerName: Springer Nature
Title Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial
URI https://link.springer.com/article/10.1038/s41467-023-39383-8
https://www.ncbi.nlm.nih.gov/pubmed/37349318
https://www.proquest.com/docview/2828554657
https://www.proquest.com/docview/2829430051
https://pubmed.ncbi.nlm.nih.gov/PMC10287640
https://doaj.org/article/ae19c89ecebf4147acfd3e5c2acc5362
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3rq9MwFD_cB4JfxPetXkcEv2m1bdIkFUR2x53X4Z2iDvZFSpKm3sHs5h7g_ntP0nYyneKXlqZpCDmP3zk9yTkAT1hBi1QYFkprRchKkYRaZ-isULfnQnEtInc4-XLIL0ZsME7HB9CWO2oWcLnXtXP1pEaL6fMf3zevUeBf1UfG5Ysl8-KO6BPSDD2uUB7CMSKTcIJ62Zj7XjPTDB0aF2hOIhaHiN20OUezf5gdrPIp_ffZoX9up_wtpuqhqn8TbjQ2JunWTHELDmx1G67VVSc3d-DLcOJ1ktJkPl0vCZLtGzJCMWkOY23IpCIe46absN0jQIxXKjiscc-LlwQ7k-Hb3vt3ZH6FUEhi4iuA3IVR__xz7yJsqiyEJmXxKrSlti42qKOs0FZrxHfNy1jqpJQIVpoaYZGi6KdxlVib2gLxjJccV0un6DzRe3BUzSp7AoQXKjERQ4NdG0Y5l9SoQlGdqZTZJIsDiNv1zE2TgtxVwpjmPhROZV7TIEca5J4GuQzg6fabeZ2A45-9zxyZtj1d8mzfMFt8zRtZzJWNMyMza6wucQShTFlQm5pEGZMioAdw2hI5bxkyd66p29GXigAeb1-jLLoAi6rsbO37uGz2qOcCuF_zxHYmVFCWoQINQO5wy85Ud99Ukyuf79vZgIKzKIBnLWP9mtff1-LBf8zzIVxPHMNHPEySUzhaLdb2EVpZK92BQzEWeJX9Nx047nYHnwZ4PzsffviIrT3e6_j_Fx0vYj8BHysnMA
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKEYIL4k2ggJHgBFYT27EdJISgUO3S7XJppV6QazsOXWnJLvsQ2j_Fb2TsJFstj956TOJYjmfmm5nMeAahF7xkZS4dJ8p7SXglKbG2AGeFhZwLI6xMw-Hkw6HoHfPPJ_nJFvrVnYUJaZUdJkagLicu_CPfDa5ByKjK5bvpDxK6RoXoatdCo2GLA7_6CS7b_G3_I9D3JaX7n472eqTtKkBczrMF8ZX1IRZm06K03lrQZ1ZUmbK0UgDOljnp4QvALxGGep_7EvBbVIJn3ObgLDCY9wq6Coo3DRIlT-T6n06otq44b8_mpEztznlEIlCMhBXgDBK1of9im4B_2bZ_p2j-EaeN6m__FrrZ2q34fcNot9GWr--ga00ny9Vd9HU4ijhnLJ6Ol3MMrPAdmKsctQe8VnhU46g3xyvS5R1gF4EKpnXhevYGw2A87O99GeDpGahXnOHYVeQeOr6UPb6PtutJ7R8iLEpDXcrBCbCOMyEUc6Y0zBYm554WWYKybj-1a8uah-4aYx3D60zphgYaaKAjDbRK0Kv1O9OmqMeFoz8EMq1HhoLc8cZk9k238q2NzwqnCu-8rWAGaVxVMp87apzLwUhI0E5HZN2ixFyf83SCnq8fg3yHoI2p_WQZx4QK-YCdCXrQ8MR6JUwyXgAoJ0htcMvGUjef1KOzWEM82JVS8DRBrzvGOl_X__fi0cWf8Qxd7x0dDvSgPzx4jG7QwPepIJTuoO3FbOmfgAG3sE-j1GB0etli-hvmhlaG
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKEYgL4k2ggJHgBFYT27EdJISgZdWlZeFApb1UxnYcutKSXfYhtH-NX8fYSbZaHr31mMSxHM_MNzOZ8QxCz3jJylw6TpT3kvBKUmJtAc4KCzkXRliZhsPJHwfi4Jh_GObDLfSrOwsT0io7TIxAXU5c-Ee-G1yDkFEFDnzVpkV83u-9mf4goYNUiLR27TQaFjn0q5_gvs1f9_eB1s8p7b3_sndA2g4DxOU8WxBfWR_iYjYtSuutBd1mRZUpSysFQG2Zkx6-BnwUYaj3uS8By0UleMZtDo4Dg3kvocuS5VmQMTmU6_87ofK64rw9p5MytTvnEZVASRJWgGNI1IYujC0D_mXn_p2u-UfMNqrC3g10vbVh8duG6W6iLV_fQlearpar2-hkMIqYZyyejpdzDGzxHRitHLWHvVZ4VOOoQ8cr0uUgYBdBC6Z14Xr2CsNgPOjvfTrC01NQtTjDscPIHXR8IXt8F23Xk9rfR1iUhrqUg0NgHWdCKOZMaZgtTM49LbIEZd1-ateWOA-dNsY6htqZ0g0NNNBARxpolaAX63emTYGPc0e_C2RajwzFueONyeybbmVdG58VThXeeVvBDNK4qmQ-d9Q4l4PBkKCdjsi6RYy5PuPvBD1dPwZZDwEcU_vJMo4J1fIBRxN0r-GJ9UqYZLwAgE6Q2uCWjaVuPqlHp7GeeLAxpeBpgl52jHW2rv_vxYPzP-MJugoCqo_6g8OH6BoNbJ8KQukO2l7Mlv4R2HIL-zgKDUZfL1pKfwPvd1q8
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Nivolumab+plus+chemoradiotherapy+in+locally-advanced+cervical+cancer%3A+the+NICOL+phase+1+trial&rft.jtitle=Nature+communications&rft.au=Rodrigues%2C+Manuel&rft.au=Vanoni%2C+Giulia&rft.au=Loap%2C+Pierre&rft.au=Dubot%2C+Coraline&rft.date=2023-06-22&rft.issn=2041-1723&rft.eissn=2041-1723&rft.volume=14&rft.issue=1&rft.spage=3698&rft_id=info:doi/10.1038%2Fs41467-023-39383-8&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2041-1723&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2041-1723&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2041-1723&client=summon